301 related articles for article (PubMed ID: 19400959)
1. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S
BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959
[TBL] [Abstract][Full Text] [Related]
2. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.
Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD
BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187
[TBL] [Abstract][Full Text] [Related]
3. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays.
Krasowski MD; Siam MG; Iyer M; Pizon AF; Giannoutsos S; Ekins S
Clin Chem; 2009 Jun; 55(6):1203-13. PubMed ID: 19342505
[TBL] [Abstract][Full Text] [Related]
4. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
Begeman A; Franssen EJF
Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
[TBL] [Abstract][Full Text] [Related]
5. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in post-mortem whole blood.
Pelletti G; Rossi F; Garagnani M; Barone R; Roffi R; Fais P; Pelotti S
Forensic Sci Int; 2020 Jul; 312():110291. PubMed ID: 32353744
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
[TBL] [Abstract][Full Text] [Related]
7. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in whole blood of drivers involved in road accidents.
Pelletti G; Garagnani M; Rossi F; Roffi R; Barone R; Pelotti S
Forensic Sci Int; 2019 Jan; 294():27-33. PubMed ID: 30447484
[TBL] [Abstract][Full Text] [Related]
8. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
[TBL] [Abstract][Full Text] [Related]
9. False-positive interferences of common urine drug screen immunoassays: a review.
Saitman A; Park HD; Fitzgerald RL
J Anal Toxicol; 2014 Sep; 38(7):387-96. PubMed ID: 24986836
[TBL] [Abstract][Full Text] [Related]
10. Optimization and validation of CEDIA drugs of abuse immunoassay tests in serum on Hitachi 912.
Kirschbaum KM; Musshoff F; Schmithausen R; Stockhausen S; Madea B
Forensic Sci Int; 2011 Oct; 212(1-3):252-5. PubMed ID: 21775079
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and applicability of Alere iCup DX 14 for rapid postmortem urine drug screening at autopsy.
Towler S; Concheiro M; Pearring S; Rodda LN
J Forensic Sci; 2021 Jan; 66(1):375-382. PubMed ID: 33022072
[TBL] [Abstract][Full Text] [Related]
12. Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants.
Phillips JE; Bogema S; Fu P; Furmaga W; Wu AH; Zic V; Hammett-Stabler C
Clin Chim Acta; 2003 Feb; 328(1-2):31-8. PubMed ID: 12559596
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the on-site immunoassay drug-screening device Triage-TOX in routine forensic autopsy.
Tominaga M; Michiue T; Maeda H
Leg Med (Tokyo); 2015 Nov; 17(6):499-502. PubMed ID: 26593997
[TBL] [Abstract][Full Text] [Related]
14. Clinical issues associated with urine testing of substances of abuse.
Eskridge KD; Guthrie SK
Pharmacotherapy; 1997; 17(3):497-510. PubMed ID: 9165553
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cutoff levels after confirmation-analysis on GC-MS and HPLC-DAD.
Kroener L; Musshoff F; Madea B
J Anal Toxicol; 2003; 27(4):205-12. PubMed ID: 12820742
[TBL] [Abstract][Full Text] [Related]
16. Hair analysis by immunological methods from the beginning to 2000.
Spiehler V
Forensic Sci Int; 2000 Jan; 107(1-3):249-59. PubMed ID: 10689577
[TBL] [Abstract][Full Text] [Related]
17. Analytic performance of immunoassays for drugs of abuse below established cutoff values.
Luzzi VI; Saunders AN; Koenig JW; Turk J; Lo SF; Garg UC; Dietzen DJ
Clin Chem; 2004 Apr; 50(4):717-22. PubMed ID: 14764642
[TBL] [Abstract][Full Text] [Related]
18. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
19. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.
Reschly-Krasowski JM; Krasowski MD
Acad Pathol; 2018; 5():2374289518811797. PubMed ID: 30480089
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups.
Lin CN; Nelson GJ; McMillin GA
J Anal Toxicol; 2013; 37(1):30-6. PubMed ID: 23144203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
